^
    Back
    Association details:
    Biomarker:RET C620R
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Int J Endocrinol
    Title:

    Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

    Excerpt:
    The MEN2A MTC patient showed the best response upon everolimus therapy. Apart from the treatment effect, the RET c.1858T>C, p.Cys620Arg mutation has been associated with a less aggressive phenotype compared to other MEN2A-related mutations such as the c.2753T>C p.Met918Thr mutation or one of the classic mutations in exon 11 at codon 634...
    DOI:
    10.1155/2015/348124